Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Weber, Donna M., Chen, Christine, Niesvizky, Ruben, Wang, Michael, Belch, Andrew, Stadtmauer, Edward A., Siegel, David, Borrello, Ivan +8 more·2007·New England Journal of Medicine

DOI 10.1056/nejmoa070596

Cited by (1,000)

Items 701–800 of 1,000

Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment
Xavier P Leleu, Charalampia A. Kyriakou, Isabelle Vande Broek, Philip Thomas Murphy, P. Bacon, P Lewis, Hélène Gilet, Benoît Arnould, Maria Teresa Petrucci · 2017 · Blood Cancer Journal
The impact of changed treatment patterns in multiple myeloma on health‐care utilisation and costs, myeloma complications, and survival: A population‐based comparison between two time periods in Denmark
Louise Hur Hannig, Lene Kongsgaard Nielsen, Rikke Ibsen, Lisen Arnheim‐Dahlström, Jakob Kjellberg, Niels Abildgaard · 2021 · European Journal Of Haematology
Smoldering multiple myeloma – Past, present, and future
Hashim Mann, Vatsala Katiyar, Cindy Varga, Raymond L. Comenzo · 2021 · Blood Reviews
Drug Repurposing by Tumor Tissue Editing
Florian Lüke, Dennis Christoph Harrer, Pan Pantziarka, Tobias Pukrop, Lina Ghibelli, Christopher Gerner, Albrecht Reichle, Daniel Heudobler · 2022 · Frontiers in Oncology
Extramedullary plasmacytomas in the context of multiple myeloma
Beatriz Aguado, Belén Íñigo, Jose Luis Sastre, Albert Oriol · 2011 · Advances in Therapy
Current Treatment Strategies with Lenalidomide in Multiple Myeloma and Future Perspectives
Alessandra Larocca, Federica Cavallo, Roberto Mina, Mario Boccadoro, Antonio Pierangelo Palumbo · 2012 · Future Oncology
Thromboembolic risk in hematological malignancies
Massimo Franchini · 2014 · Clinical Chemistry and Laboratory Medicine (CCLM)
Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma
Sarah M Anderson, Bradley Beck, Susan Sterud, Robin Lockhorst, Surachat Ngorsuraches · 2018 · Journal of Oncology Pharmacy Practice
Going the distance: Are we losing patients along the multiple myeloma treatment pathway?
Evangelos Terpos, Florence Suzan, Hartmut Goldschmidt · 2018 · Critical Reviews in Oncology/Hematology
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
Alexander Egle, Michael Steurer, Thomas Melchardt, Lukas Weiß, Franz Josef Gassner, Nadja Zaborsky, Roland Geisberger, Kemal Catakovic, Tanja Nicole Hartmann, Lisa Pleyer et al. · 2018 · Annals of Hematology
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
Katharina Kriegsmann, Marc‐Andrea Baertsch, Mohamed H.S. Awwad, Maximilian Merz, Dirk Hose, Anja Seckinger, Anna Sophia Jauch, Natália Becker, Axel Benner, Marc Steffen Raab et al. · 2019 · Blood Cancer Journal
Remission Induction With Lenalidomide Alone in a Patient With Previously Untreated Plasmablastic Myeloma: A Case Report
Taimur Sher, Kena C. Miller, Kelvin P. Lee, Asher Alban Chanan-Khan · 2009 · Clinical Lymphoma & Myeloma
Treatment of Hematologic Neoplasms with New Immunomodulatory Drugs (IMiDs)
Peter H. Wiernik · 2008 · Current Treatment Options in Oncology
Pulmonary toxicity associated with the use of lenalidomide: Case report of late-onset acute respiratory distress syndrome and literature review
Julie Mankikian, Bertrand Lioger, Élisabeth Diot, PN d'Halluin, Séverine Lissandre, Sylvain Marchand-Adam, E. Mercier, Frédérique Beau-Salinas · 2013 · Heart & Lung
Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects
Alessandro Corso, Patrizia Zappasodi, Luciana Barbarano, Maria Teresa Petrucci, Antonio Palumbo, Tommaso Caravita, Silvia Mangiacavalli, Anna Maria Cafro, Marzia Varettoni, Francesca Gay et al. · 2009 · Leukemia Research
Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone
Haowei Sun, Eshetu G. Atenafu, Elizabeth Yeboah, Donna Ellen Reece, Suzanne Trudel, Vishal Kukreti, Esther Masih‐Khan, Andrew Winter, Christine I. Chen · 2014 · Leukemia & lymphoma/Leukemia and lymphoma
Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA
Norie Murayama, Hiroshi Suemizu, Shotaro Uehara, Takashi Kusama, Marina Mitsui, Yusuke Kamiya, Makiko Shimizu, Frederick Peter Guengerich, Hiroshi Yamazaki · 2018 · The Journal of Toxicological Sciences
Targeted therapy of multiple myeloma
Robert A. Kyle · 2012 · Hematology
From serendipity to strategy: molecular glue degraders in cancer therapeutics
Darling, Sarah, Bajrami, Ilirjana, West, Stephen C. · 2025 · Critical Reviews in Biochemistry and Molecular Biology
Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions
Sung‐Hoon Jung, Youngil Koh, Min Kyoung Kim, Jin Seok Kim, Joonho Moon, Chang‐Ki Min, Dok Hyun Yoon, Sung Soo Yoon, Je‐Jung Lee, Chae Moon Hong et al. · 2025 · Blood Research
Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value
J. Gaultney, W. Redekop, P. Sonneveld, C. Uyl-de Groot · 2012 · Expert Review of Anticancer Therapy
Development of Early Treatment Strategies for High-Risk Myeloma Precursor Disease in the Future
Ola Landgren, S. Vincent Rajkumar · 2011 · Seminars in Hematology
Adherence to and effectiveness of lenalidomide after 1 year of treatment in a real world setting
Fiorenzo Santoleri, Ruggero Lasala, Elena Ranucci, Marco Rocchi, Stefano Pulini, Anna Maria Morelli, Antonio Spadano, Alberto Costantini · 2020 · Journal of Oncology Pharmacy Practice
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment
Meletios Athanasios Dimopoulos, Joseph R Mikhael, Evangelos Terpos, Xavier P Leleu, Philippe Moreau, Joan Bladé, Jin Seok Kim, Keith E Stockerl-Goldstein, Paul Gerard Guy Richardson · 2022 · Therapeutic Advances in Hematology
The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease
Paul Gerard Guy Richardson, María‐Victoria Mateos, Annette Juul Vangsted, Karthik Ramasamy, Niels Abildgaard, Phoebe Joy Ho, Hang Quach, Nizar Jacques Bahlis · 2022 · Expert Review of Proteomics
Mature results of MM‐011: A phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma
Aleksandr Lazaryan, Mohamad A. Hussein, Frederic J. Reu, Beth M Faiman, Becky Habecker, Mary Ann Karam, Janice Reed, Kimberly M. Hamilton, Joel A. Waksman, Kellie Bruening et al. · 2013 · American Journal of Hematology
Challenges in multiple myeloma diagnosis and treatment
Saulius Kazmiems Girnius, Nikhil C. Munshi · 2013 · Leukemia Supplements
“Real world” outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the “rete ematologica pugliese”
Giuseppe Mele, Angela Melpignano, Giovanni Quarta, Giuseppe A. Palumbo, Silvana Franca Capalbo, Antonietta Pia Falcone, Nicola Cascavilla, G. Palazzo, Patrizio Mazza, Emilio Iannitto M. D et al. · 2014 · Leukemia Research
Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma
KMF investigators, Tsutomu Kobayashi, Junya Kuroda, Shin‐ichi Fuchida, Hitomi Kaneko, Hideo Yagi, Hirohiko Shibayama, Hirokazu Tanaka, Satoru Kosugi, Nobuhiko Uoshima et al. · 2014 · International Journal of Hematology
Effectiveness and safety of high‐dose cyclophosphamide as salvage therapy for high‐risk multiple myeloma and plasma cell leukemia refractory to new biological agents
Guillermo L Rivell, Chris Y. Brunson, Laura Milligan, Robert Kenneth Stuart, Luciano J. Costa · 2011 · American Journal of Hematology
Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant
Francesco Spina, Vittorio Montefusco, Claudia Crippa, Annalisa Citro, Simona Sammassimo, Barbara Olivero, Silvia Gentili, Monica Galli, Tommasina Guglielmelli, Davide Rossi et al. · 2011 · Leukemia & lymphoma/Leukemia and lymphoma
Comparing venous thromboembolism prophylactic strategies for ambulatory multiple myeloma patients on immunomodulatory drug therapy
Ruth J Dede, Jane M. Pruemer · 2015 · Journal of Oncology Pharmacy Practice
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR‐MM)
Xavier P Leleu, Evangelos Terpos, Ramón García‐Sánz, Julian P. Cooney, Peter O’Gorman, Jiří Minařík, Richard Greil, Catherine D. Williams, Diep Gray, Zsolt Roland Szabó · 2016 · American Journal of Hematology
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma
Tomer Martin Mark, Danielle Guarneri, Peter A. Forsberg, Adriana Rossi, Roger Niles Pearse, Arthur Perry, Karen A. Pekle, Linda Tegnestam, June Greenberg, Tsiporah B. Shore et al. · 2017 · Transplantation and Cellular Therapy
Renal, GI, and Peripheral Nerves: Evidence-Based Recommendations for the Management of Symptoms and Care for Patients With Multiple Myeloma
Beth M Faiman, Deborah S. Doss, Kathleen Colson, Patricia A Mangan, Tracy King, Joseph D Tariman, and Board · 2017 · Clinical journal of oncology nursing
Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center
Patrick Yau, Victor Hugo Jimenez-Zepeda, Kyla Bailey, Peter Raymond Duggan, Jason Tay, Nizar Jacques Bahlis, Paola E. Neri, Sylvia McCulloch · 2019 · Leukemia & lymphoma/Leukemia and lymphoma
The predictive value of serum myeloma protein in solitary plasmacytoma
Won Ick Chang, Hyeon Kang Koh, Sung‐Soo Yoon, Han‐Soo Kim, Keun‐Yong Eom, Il Han Kim · 2020 · Radiation Oncology Journal
Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma
Sara Bringhen, Francesca Gay, Chiara Pautasso, Chiara Cerrato, Mario Boccadoro, Antonio Pierangelo Palumbo · 2012 · Expert Opinion on Drug Metabolism & Toxicology
Chemotherapeutic Agents Increase the Risk for Pulmonary Function Test Abnormalities in Patients With Multiple Myeloma
Jarrod T. Bruce, Jerry M. Tran, Gary S. Phillips, Pat Elder, John G. Mastronarde, Steven Michael Devine, Craig C. Hofmeister, Karen L. Wood · 2012 · Clinical Lymphoma Myeloma & Leukemia
How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions
Massimo Offidani, Laura Corvatta, Fortunato Morabito, Massimo Gentile, Pellegrino Musto, Pietro Leoni, Antonio Pierangelo Palumbo · 2011 · Expert Opinion on Investigational Drugs
In pursuit of the allo-immune response in multiple myeloma: where do we go from here?
Gordon Cook, Jenny M. Bird, D I Marks · 2008 · Bone Marrow Transplantation
Drug-induced Interstitial Pneumonitis due to Low-dose Lenalidomide
Kei Kunimasa, Tomoaki Ueda, Machiko Arita, Takeshi Maeda, Machiko Hotta, Tadashi Ishida · 2012 · Internal Medicine
Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma
Emmanuelle Le Ray, Sundar Jagannath, Antonio Pierangelo Palumbo · 2015 · Expert Review of Hematology
Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21 st century
Janick G. Weberpals, Dianne D. Pulte, Lina Jansen, Sabine Luttmann, Bernd Holleczek, Alice Nennecke, Meike Ressing, Alexander Katalinic, Maximilian Merz, Hermann Brenner · 2017 · Haematologica
Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium
Elżbieta Iskierka‐Jazdzewska, Federico Canzian, Anna Stępień, Alessandro Martino, Daniele Campa, Angelica Stein, Małgorzata Krawczyk‐Kuliś, Malwina Rybicka‐Ramos, Sławomira Kyrcz‐Krzemień, Aleksandra K. Butrym et al. · 2019 · Leukemia & lymphoma/Leukemia and lymphoma
The paradoxical pharmacological mechanisms of lenalidomide and bortezomib in the treatment of multiple myeloma
Busong Wang, Jingjing Duan, Liang Zhou · 2021 · Anti-Cancer Drugs
Lenalidomide
Katja Christina Weisel, Lothar Kanz · 2014 · Recent results in cancer research/Recent Results in Cancer Research
Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World Experience
Aya Nakaya, Shinya� Fujita, Atsushi� Satake, Takahisa� Nakanishi, Yoshiko� Azuma, Yukie� Tsubokura, Masaaki� Hotta, Hideaki� Yoshimura, Kazuyoshi� Ishii, Tomoki� Ito et al. · 2017 · Acta Haematologica
Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relapsed/Refractory Multiple Myeloma
Omar Nadeem, Sikander Ailawadhi, Jack Khouri, Louis S. Williams, Donna Catamero, Kathryn T. Maples, Jesús G. Berdeja · 2024 · Cancers
Relapsed and Refractory Multiple Myeloma
Silvia Gentili, Sagar Lonial · 2014 · Hematology/Oncology Clinics of North America
Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
Liping Liu, Ningning Zhao, Wenjun Xu, Zhixin Sheng, Lida Wang · 2016 · Journal of Hematology & Oncology
Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma
Yaohua Cao, Lina Zhao, Tiantian Zhang, Weiling Cao · 2021 · Frontiers in Pharmacology
SETDB1 induces lenalidomide resistance in multiple myeloma cells via epithelial‑mesenchymal transition and PI3K/AKT pathway activation
Xiaoli Qian, Yang Yang, Yingfen Deng, Yali Liu, Yuwen Zhou, Fang Han, Yue Xu, Hongjian Yuan · 2023 · Experimental and Therapeutic Medicine
Lenalidomide in the treatment of anti‐myelin‐associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose
Amro Maher Stino, Naresh Bumma, Rachel M. Smith, Long Davalos, Jeffrey A. Allen, Jing Christine Ye, Matthew James Pianko, Erica Leigh Campagnaro, Cassandra Fierro, Abdelrahman Awad et al. · 2023 · European Journal of Neurology
An update on the use of lenalidomide for the treatment of multiple myeloma
Flora Zagouri, Evangelos Terpos, Efstathios Kastritis, Meletios Athanasios Dimopoulos · 2015 · Expert Opinion on Pharmacotherapy
Helical tomotherapy and systemic targeted therapies in solitary plasmacytoma: Pilot study
Nadia Wiazzane · 2013 · World Journal of Radiology
Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
Ravi Vij · 2011 · PubMed
Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment
Cristina M. Joao, José Guilherme de Freitas, Fernando Manuel Ribeiro Gomes, Catarina Geraldes, Inês Coelho, Manuel L Neves, Paulo Lúcio, Susana Esteves, Graça Vasconcelos Esteves · 2016 · Annals of Hematology
Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Panagiotis Samaras, Mario J. Bargetzi, Daniel C. Betticher, Michel André Duchosal, Dominik A. Heim, Urs Hess, Nicolas Ketterer, Erika Lerch, Thomas Matthes, Ulrich Mey et al. · 2015 · Swiss Medical Weekly
Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Shinsuke Iida, Masashi Wakabayashi, Kunihiro Tsukasaki, Kenichi Miyamoto, Dai Maruyama, Kazuhito Yamamoto, Yoshifusa Takatsuka, Shigeru Kusumoto, Junya Kuroda, Kiyoshi Ando et al. · 2018 · Cancer Science
Multiple myeloma in Saudi Arabia: Consensus of the Saudi lymphoma/myeloma group
Ahmed S. Alaskar, Ahmad S. Alsaeed, Fahad Z. Alsharif, Hani Alhashmi, Mubarak S. AlGhamdi · 2019 · Journal of Applied Hematology
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future
Benjamin T. Diamond, Kylee H. Maclachlan, David J. Chung, Alexander M. Lesokhin, Ola Landgren · 2020 · Best Practice & Research Clinical Haematology
Chemotherapy-Associated Thrombosis
Aneel A. Ashrani, S. Vincent Rajkumar · 2009 · Cancer treatment and research
Phase II study of pegylated liposomal doxorubicin, low‐dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma
Rachid Baz, Kenneth H. Shain, Mohamad A. Hussein, Ji‐Hyun Lee, Daniel M. Sullivan, Elizabeth Finley Oliver, Lisa Ann Nardelli, Lisa Nodzon, Xiuhua Zhao, Jose Leonel Ochoa-Bayona et al. · 2013 · American Journal of Hematology
Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients
Kamel Amraoui, Karim Belhadj, Bernard Maître, Caroline Jannière-Nartey, Jehan Dupuis · 2013 · European Respiratory Review
Multiple myeloma: detecting the effects of new treatments
Benjamin Djulbegović, Ambuj Kumar · 2008 · The Lancet
Arterial Thrombosis With Immunomodulatory Derivatives in the Treatment of Multiple Myeloma: A Single-Center Case Series and Review of the Literature
Mike G. Martin, Ravi Vij · 2009 · Clinical Lymphoma & Myeloma
New treatments for myeloma
I Azaïs, Rachel Brault, Françoise Debiais · 2009 · Joint Bone Spine
New drugs in multiple myeloma
James R. Berenson, Ori Yellin · 2008 · Current Opinion in Supportive and Palliative Care
Treatment of Relapsed/Refractory Multiple Myeloma
Paola E. Neri, Nizar Jacques Bahlis, Claudia E. Paba‐Prada, Paul Gerard Guy Richardson · 2016 · Cancer treatment and research
Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma
Klaus Podar, Martin Pecherstorfer · 2017 · Expert Opinion on Pharmacotherapy
Treatment of Multiple Myeloma: A Comprehensive Review
Robert A. Kyle, S. Vincent Rajkumar · 2009 · Clinical Cancer Reviews
The molecular biology of multiple myeloma
Wee Joo Chng, Peter Leif Bergsagel · 2019 · Wiley eBooks
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma
Francesca Gay, S. Vincent Rajkumar, Patrizia Falco, Shaji Kunnathu Kumar, Angela A. Dispenzieri, Maria Teresa Petrucci, Morie Abraham Gertz, Mario Boccadoro, A. Keith Stewart, Antonio Palumbo · 2010 · European Journal Of Haematology
A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma
Shinsuke Iida, Tohru Izumi, Takuya Komeno, Yasuhito Terui, Takaaki Chou, Takashi Ikeda, Deborah T. Berg, Shinichi Fukunaga, Kenkichi Sugiura, Makoto Sasaki · 2021 · International Journal of Clinical Oncology
Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
Adrián Macías Alegre, Isabel Vicuña, Beatriz Aguado · 2011 · Clinical Medicine Insights Oncology
Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?
Heinz Ludwig, Peter Sonneveld · 2012 · Leukemia Research
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines
Maria Cosenza, Monica Civallero, Giulia Grisendi, Luigi Marcheselli, Erika Roat, Alessia Bari, Stefano Sacchi · 2012 · Annals of Hematology
Handbook of Multiple Myeloma
Jean‐Luc Harousseau, Mohamad Mohty · 2015 · Springer eBooks
Low frequency of CD3+CD4+CD161+ T cells correlates with the occurrence of infections in refractory/relapsed multiple myeloma patients receiving lenalidomide plus low-dose dexamethasone treatment
Sung‐Eun Lee, Ji‐Young Lim, Da‐Bin Ryu, Tae‐Woo Kim, Sung Soo Park, Young‐Woo Jeon, Jae‐Ho Yoon, Byung‐Sik Cho, Ki‐Seong Eom, Yoo‐Jin Kim et al. · 2018 · Annals of Hematology
Agentes inmunomoduladores (IMiDs): herramientas para el tratamiento del mieloma múltiple
Diego Fernández‐Lázaro, Cesar Ignacio Fernandez-Lazaro, Alberto Caballero-García, Alfredo Córdova · 2018 · Revista médica de Chile
Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
María‐Victoria Mateos, Felipe Prósper, Jesús Martín, Enrique M. Ocio, Albert Oriol, Cristina Motlló, Jean‐Marie Michot, Isidro Jarque, Rebeca Iglesias, María Solé et al. · 2022 · Cancer Medicine
Managing multiple myeloma in the elderly: are we making progress?
Hang Quach, Henry Miles Prince, Andrew G Spencer · 2011 · Expert Review of Hematology
A practical approach to relapsed multiple myeloma
Joseph R Mikhael · 2014 · Hematology
Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies
Susan Blumel, Jackie Broadway-Duren · 2014 · Journal of the Advanced Practitioner in Oncology
Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma
Benedetto Bruno, Luisa Giaccone, Roberto Sorasio, Mario Boccadoro · 2009 · Seminars in Hematology
Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma
Nobuhiko Nakamura, Nobuhiro Kanemura, Yuhei Shibata, Takuro Matsumoto, Ryoko Mabuchi, Hiroshi Nakamura, Junichi Kitagawa, Naoe Goto, Takeshi Hara, Hisashi Tsurumi et al. · 2013 · Leukemia & lymphoma/Leukemia and lymphoma
Lenalidomide-Induced Graft-Vs.-Leukemia Effect in a Patient With Chronic Lymphocytic Leukemia Who Relapsed After Allogeneic Stem Cell Transplant
Rohtesh S. Mehta, Antonio Di Stasi, Chitra M. Hosing, Nina D. Shah, Katayoun Rezvani, Amin Majid Alousi, Susan Mary O'Brien, William G. Wierda, Michael J. Keating, Elizabeth J. Shpall · 2014 · Clinical Lymphoma Myeloma & Leukemia
CYTOMEGALOVIRUS RETINITIS AFTER TREATMENT WITH LENALIDOMIDE FOR MULTIPLE MYELOMA
Hui Yin Lim, David Francis, Jonathan Yeoh, Lyndell L. Lim · 2013 · Retinal Cases & Brief Reports
Multiple Myeloma and Related Disorders
S. Vincent Rajkumar, Angela A. Dispenzieri · 2020 · Elsevier eBooks
Treatment options for relapse after autograft in multiple myeloma – report from an EBMT educational meeting
Laurent Garderet, Gordon Cook, Holger W. Auner, Benedetto Bruno, Henk M. Lokhorst, José Antonio Pérez‐Simón, Firoozeh Sahebi, Christof Scheid, Curly Morris, Anja van Biezen et al. · 2016 · Leukemia & lymphoma/Leukemia and lymphoma
Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma
Ajay K. Nooka, Sagar Lonial · 2019 · The Cancer Journal
The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma
Almuth Maria Anni Merz, Maximilian Merz, Jens Hillengaß, Sarah A. Holstein, Philip L. McCarthy · 2019 · Expert Review of Anticancer Therapy
Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients
Tommasina Guglielmelli, Maria Teresa Petrucci, Giuseppe Nicola Saglio, Antonio Palumbo · 2010 · British Journal of Haematology
Human preclinical multiple myeloma in vitro models for disease modeling and therapy screening
Mikayla Ybarra, Jaehun Lee, Yun-Ya Chen, Jianhong Lin, Jianjun Zhao, Chao Ma · 2025 · Journal of Biological Engineering
Novel Drugs in Myeloma: Harnessing Tumour Biology to Treat Myeloma
Kevin D. Boyd, Faith E. Davies, Gareth John Morgan · 2011 · Recent results in cancer research/Recent Results in Cancer Research
Monoclonal Antibody-Based Immunotherapy for Multiple Myeloma
Ivetta Danylesko, Katia Beider, Avichai Shimoni, Arnon Nagler · 2012 · Immunotherapy
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
Marc‐Andrea Baertsch, Jana Schlenzka, Elias K. Mai, Maximilian Merz, Jens Hillengaß, Marc Steffen Raab, Dirk Hose, Patrick Wuchter, Anthony Dick Ho, Anna Sophia Jauch et al. · 2016 · BMC Cancer
Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta‐analysis of phase 3 randomized controlled trials
Binod Dhakal, Ravi Kishore Narra, Smith Giri, Anikó Szabó, Timothy L. Smunt, Sanjoy Ghose, Lakshmi Kant Pathak, Madan Raj Aryal, Mehdi Hamadani, Saurabh Chhabra et al. · 2020 · Cancer
Multiple Myeloma and Related Disorders
S. Vincent Rajkumar, Angela A. Dispenzieri · 2014 · Elsevier eBooks